The PROMISE Study: PROphylaxis of Migraine with SEglor® (Dihydroergotamine Mesilate) in French Primary Care
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Introduction: Seglor® capsules, a unique modified-release formulation of dihydroergotamine mesilate, have long been in clinical use in France for migraine prophylaxis. The aim of the PROMISE (PROphylaxis of Migraine with SEglor®) study was to establish the efficacy and tolerability of Seglor® in the prevention of migraine in a general practice setting.
Methods: The PROMISE study was a double blind, placebo-controlled, parallel-group study carried out in primary care practice. It included 363 migraine patients treated with Seglor® or placebo for 5 months after a 1-month placebo run-in phase.
Results: Migraine attack frequency (primary efficacy criterion) decreased markedly in the two treatment groups so that the difference in favour of Seglor® did not reach statistical significance. However, most secondary outcome measures (duration of single attack, total duration of attacks over 1 month, consumption of mild opiate analgesics, subjective improvement) improved to a significantly greater degree in patients receiving Seglor® than in those receiving placebo. In the 84.5% of patients who had impaired quality of life at entry, the percentage of reduction in attack frequency and most other efficacy measures showed significant improvement with Seglor®. The safety profile for Seglor® was comparable to that of placebo.
Conclusion: These results support the effectiveness of Seglor® in patients with migraine-related quality-of-life impairment. The findings of the PROMISE study also suggest that patients’ quality of life should be assessed systematically before initiating a preventive treatment for migraine.
- The PROMISE Study: PROphylaxis of Migraine with SEglor® (Dihydroergotamine Mesilate) in French Primary Care
Volume 18, Issue 15 , pp 1149-1163
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Service de Médecine Interne 4, Centre Migraines et Céphalées, Hôpital Louis Mourier, 178 rue des Renouillers, 92700, Colombes, France
- 2. Department of Evaluation and Treatment of Pain, Pasteur Hospital, Nice, France
- 3. Rangueil University Teaching Hospital, Toulouse, France
- 4. Pontchaillou Hospital, Rennes, France
- 5. Neurological Clinic, Salengro Hospital, Lille, France
- 6. Schwarz Pharma France, Boulogne-Billancourt, France